Evidence map›Paper›PMID 28170423›Full record

ArticlePloS one2017

Nur77 deletion impairs muscle growth during developmental myogenesis and muscle regeneration in mice.

Omar Cortez-Toledo, Caitlin Schnair, Peer Sangngern, Daniel Metzger, Lily C Chao

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Controversy and multiple roles of the solitary nucleus receptor Nur77 in disease and physiology.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Skeletal Muscle Regeneration in Cardiotoxin-Induced Muscle Injury Models.International journal of molecular sciences · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Omar Cortez-ToledoThe Center for Endocrinology, Diabetes, and Metabolism, The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California, United States of America.
Caitlin SchnairThe Center for Endocrinology, Diabetes, and Metabolism, The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California, United States of America.
Peer SangngernThe Center for Endocrinology, Diabetes, and Metabolism, The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California, United States of America.
Daniel MetzgerInstitut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS UMR7104/INSERM U964/Université de Strasbourg, Illkirch, France.
Lily C ChaoThe Center for Endocrinology, Diabetes, and Metabolism, The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California, United States of America.ORCID http://orcid.org/0000-0002-6294-0589

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Muscle atrophy is a prevalent condition in illness and aging. Identifying novel pathways that control muscle mass may lead to therapeutic advancement. We previously identified Nur77 as a transcriptional regulator of glycolysis in skeletal muscle. More recently, we showed that Nur77 expression also controls myofiber size in mice. It was unknown, however, whether Nur77's regulation of muscle size begins during developmental myogenesis or only in adulthood. To determine the importance of Nur77 throughout muscle growth, we examined myofiber size at E18.5, 3 weeks postnatal age, and in young adult mice. Using the global Nur77-/- mice, we showed that Nur77 deficiency reduced myofiber size as early as E18.5. The reduction in myofiber size became more pronounced by 3 weeks of age. We observed comparable reduction in myofiber size in young myofiber-specific Nur77-knockout mice. These findings suggest that Nur77's effect on muscle growth is intrinsic to its expression in differentiating myofibers, and not dependent on its expression in myogenic stem cells. To determine the importance of Nur77 expression in muscle accretion in mature mice, we generated an inducible-, muscle-specific, Nur77-deficient mouse model. We demonstrated that tamoxifen-induced deletion of Nur77 in 3-month-old mice reduced myofiber size. This change was accompanied by increased activity of Smad2 and FoxO3, two negative regulators of muscle mass. The role of Nur77 in muscle growth was further elaborated in the cardiotoxin-induced muscle regeneration model. Compared to wildtype mice, regenerated myofibers were smaller in Nur77-/- mice. However, when normalized to saline-injected muscle, the recovery of sarcoplasmic area was comparable between Nur77-/- and wildtype mice. These findings suggest that Nur77 deficiency compromises myofiber growth, but not the regenerative capacity of myogenic progenitor cells. Collectively, the findings presented here demonstrate Nur77 as an important regulator of muscle growth both during prenatal and postnatal myogenesis.

Indexed as

Gene DeletionAnimalsCardiotoxinsCell CycleCell SizeGene ExpressionMiceMice, KnockoutMuscle DevelopmentMuscle Fibers, SkeletalMuscle, SkeletalNuclear Receptor Subfamily 4, Group A, Member 1RegenerationCardiotoxinsNr4a1 protein, mouseNuclear Receptor Subfamily 4, Group A, Member 1

Identifiers

PMID28170423
PMCPMC5295706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.